Bariatric Surgery for the Reduction of cArdioVascular Events Feasibility Trial

Hamilton Health Sciences Corporation60 enrolled

Overview

Pilot multicentre, open-label, parallel-arm randomized controlled trial (RCT) of 60 patients to demonstrate the feasibility of enrolling patients with high-risk cardiovascular disease (CVD) into an RCT of bariatric surgery versus medical weight management (MWM).

STUDY OBJECTIVE The primary objective of this pilot study is to assess the feasibility of an RCT of bariatric surgery compared to MWM in patients with morbid obesity and high-risk CVD. If we can demonstrate that this trial is feasible, the next step would be to conduct a large-scale RCT to evaluate the efficacy of bariatric surgery for the reduction of cardiovascular complications in this patient population. STUDY AIMS: 1. To demonstrate that enrolment of high-risk CVD patients into a bariatric surgery RCT is feasible. 2. To show that it is feasible to perform bariatric surgery in \>80% of patients in the intervention arm within 30 days of randomization. 3. To obtain preliminary information on the perioperative risks of bariatric surgery in patients with high-risk CVD. STUDY HYPOTHESES Study enrollment will be feasible at a rate of at least 1.25 patients per centre per month. Timely delivery of the intervention is possible, with \>80% of patients undergoing bariatric surgery within 30 days of randomization. The rate of crossover between the control and intervention arms will be low at \<2.5% per year. 30-day mortality rates in the intervention group will be comparable to that of an age and gender matched cohort without CVD who had bariatric surgery at the 2 study sites during the study period. DESIGN The present study is a multicentre, open-label, parallel-arm feasibility RCT with blinded endpoint assessment (PROBE design) of bariatric surgery compared to MWM in patients with morbid obesity and high-risk CVD. Individuals who meet study eligibility criteria will be randomized in 1:1 fashion to bariatric surgery (intervention arm) or MWM (control arm). Bariatric surgery will consist of laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy, performed at the discretion of the surgeon and according to local standards.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Obesity, Morbid Cardiovascular Diseases

Interventions

Bariatric surgeryPROCEDURE

Although there may be slight variation by centre, Gastric Bypass generally involves creation of a 30-50 cc stomach pouch, which is anastamosed with a Roux limb of jejunum 75-100 cm in length and a biliary limb of 20-30 cm in length. The operation creates a small gastric pouch, with nutrients bypassing the duodenum and proximal jejunum. Sleeve Gastrectomy involves decreasing the size of the stomach to approximately 15% of its original size by resecting a large portion of the stomach along the greater curvature.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Body mass index \>35 kg/m2 2. Age ≥18 years 3. High-risk CVD, defined as the presence of any one of the following: 1. History of MI, multi-vessel percutaneous coronary intervention or multi-vessel coronary artery bypass grafting; OR 2. Coronary artery disease (CAD) with documented stenoses ≥50% in 2 or more major coronary arteries; OR 3. Symptomatic HF (New York Heart Association class ≥2) on optimal HF therapy for ≥3 months, AND documented HF hospitalization within the last 12 months, OR baseline N-terminal pro B-type natriuretic peptide (NT-pro BNP) \>400 pg/ml;44, 45 OR 4. Documented AF with CHA2DS2-VASc stroke risk score (congestive heart failure/ left ventricular dysfunction, hypertension, age ≥ 75 years \[2 points\], diabetes, history of stroke/ transient ischemic attack \[2 points\], vascular disease, age 65-74 years and female sex) of ≥2; OR 5. History of ischemic stroke; OR 6. Peripheral artery disease, defined as prior aorto-femoral bypass surgery, limb bypass surgery, or percutaneous transluminal angioplasty revascularization of the iliac, infra-inguinal arteries or carotids; or limb or foot amputation for arterial vascular disease; or ≥50% carotid or peripheral artery stenosis 4. Patient is deemed eligible to undergo bariatric surgery according to local practice guidelines Exclusion Criteria: 1. Hospital admission for HF within 30 days of enrolment 2. Myocardial infarction, stroke or coronary revascularization in prior 30 days. 3. Percutaneous coronary intervention with a drug eluting stent in prior 90 days. 4. Pregnancy 5. Contraindication to bariatric surgery (atrophic gastritis, diabetes mellitus type 1, prior laparotomy, liver cirrhosis with portal hypertension, uncontrolled drug or alcohol dependence, prior bariatric surgery, massive ventral hernia, severe chronic obstructive pulmonary disease) 6. Life expectancy \<2 years from non-cardiovascular causes. 7. Risk of general anesthesia deemed too excessive 8. Current drug or alcohol dependency (within 6 months of referral) 9. Recent major cancer (life threatening, within last 2 years) 10. Untreated or inadequately treated psychiatric illness 11. Inability to provide informed consent

Locations (1)

St. Joseph's Healthcare Hamilton

Hamilton, Ontario, Canada

RECRUITING

Outcomes

Primary Outcomes

Recruitment rate

Recruitment rate (target of 60 patients over 24 months or 1.25 patients per centre per month)

Time frame: 24 months (or when recruitment is complete)

Time to intervention administration

Target of bariatric surgery performed within 30 days of randomization in \>80%

Time frame: 30 days

Crossover rate

Crossover rate between control and intervention arm

Time frame: At study completion (an average of 1.5 years follow-up)

Secondary Outcomes

Change in weight at 1 year

Change in weight in kilograms at 1 year

Time frame: 12 months

Change in BMI at 1 year

BMI (kg/m\^2) will be calculated using weight in kg at 1 year, and height

Time frame: 12 months

Composite outcome of cardiovascular mortality, myocardial infarction (MI), stroke and hospitalization for heart failure (HF)

Composite outcome of cardiovascular mortality, myocardial infarction, stroke and hospitalization for heart failure

Time frame: 12 months, and through study completion (an average of 1.5 years follow-up)

Change in percent excess weight loss (%) at 1 year

Excess weight loss is a standard outcome measure in obesity research. It is calculated as the percentage of excess body weight lost after surgery. Excess body weight (kg) is calculated as current weight (kg) minus ideal body weight (kg) for a given height. Ideal body weight (kg) is taken from standardized tables.

Central Contacts

Tara McCready, PhD, MBA

CONTACT

905-521-2100 tara.mccready@phri.ca

Wanna Fong

CONTACT

905-521-2100 wanna.fong@phri.ca

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.